We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America
News

Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America

Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America
News

Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stellar's second patent issued as United States Patent No. 8,084,441, entitled "Cystitis Treatment with High Dose Chondroitin Sulfate," relates to the treatment of IC/PBS by instillation of an optimized unit dose of chondroitin sulfate that is at least 350mgs or more. The Company expects this patent to issue. Once issued, the patent will expire in 2023.

Rob Harris, Stellar's President and Chief Executive Officer, commented, "This second patent expands the scope of Stellar's exclusive rights in the United States for Uracyst, and further validates the innovative nature of Stellar's approach to the treatment of interstitial cystitis/painful bladder syndrome, and underscores the Company's position as a leader in this field". Mr. Harris went on to say that several companies have expressed an interest in the US rights to Uracyst.

Advertisement